Zobrazeno 1 - 10
of 925
pro vyhledávání: '"sodium glucose cotransporter-2 inhibitors"'
Autor:
Han Liu, Bingchen Jiang, Rui Hua, Xuehao Liu, Bao Qiao, Xiangxin Zhang, Xilong Liu, Wenjun Wang, Qiuhuan Yuan, Bailu Wang, Shujian Wei, Yuguo Chen
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-14 (2024)
Abstract Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are now recommended for patients with heart failure, but the mechanisms that underlie the protective role of SGLT2i in cardiac remodeling remain unclear. Aldehyde dehydrogenase 2
Externí odkaz:
https://doaj.org/article/53dfa8dfb86c418596c46e2faf05375e
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 20, Iss 3, Pp 331-339 (2024)
From modern perspective, hyperuricemia should be considered as a trigger of inflammatory activity in tissues and organs, leading to the formation of tophi, arthropathy, kidneys and cardiovascular system damage. Similarly, hypercholesterolemia, a prov
Externí odkaz:
https://doaj.org/article/4d8e42bd6f4c47d7b1be8bc3e10783a4
Autor:
Jingya Wang, Krishnarajah Nirantharakumar, Christopher Sainsbury, David J. Moore, Alan Sinclair, G. Neil Thomas, Wasim Hanif, Megha Singh, Luyuan Tan, Zhaonan Wang, Nikita Simms-Williams, Mi Yao, M. Niluka Gunathilaka, Pushpa Singh, Konstantinos Toulis, Apostolos Tsapas, Dyuti Coomar, Malcolm James Price
Publikováno v:
Systematic Reviews, Vol 13, Iss 1, Pp 1-9 (2024)
Abstract Background Due to increasing life expectancy, almost half of people with type 2 diabetes are aged 65 years or over worldwide. When metformin alone does not control blood sugar, the choice of which second-line therapy to prescribe next is not
Externí odkaz:
https://doaj.org/article/dfb874c27dc74b1d8dfacc9e5f2d9912
Autor:
Jimmy Gonzalez, Chintan V. Dave
Publikováno v:
BMC Cardiovascular Disorders, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are recommended for treatment of heart failure (HF), regardless of type 2 diabetes (T2DM) status. However, limited data exist on SGLT2i prescribing in HF patients without T2DM or
Externí odkaz:
https://doaj.org/article/d2a4da3b06ab4098b125920507df312d
Autor:
T. N. Markova, M. S. Stas
Publikováno v:
Сахарный диабет, Vol 27, Iss 2, Pp 174-184 (2024)
Patients with type 2 diabetes mellitus (T2DM) are at high risk of adverse outcomes in coronavirus infection (COVID-19). Despite the gradual resolution of the pandemic, new strains of the virus are emerging, characterized by high contagiousness, and t
Externí odkaz:
https://doaj.org/article/ae97781e6ea94104a58794a1475d9f60
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract This study evaluated the effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on cancer development, particularly in hepatocellular carcinoma (HCC), in individuals with concomitant fatty liver disease (FLD) and type 2 diabetes mellit
Externí odkaz:
https://doaj.org/article/0b2e6bce5904444ab0b15f2958167ef2
Autor:
Hamidreza Soleimani, Behrad Saeedian, Yeganeh Pasebani, Nastaran Babajani, Amirreza Pashapour Yeganeh, Pegah Bahirai, Hossein Navid, Ahmad Amin, Marc D. Samsky, Micheal G. Nanna, Kaveh Hosseini
Publikováno v:
ESC Heart Failure, Vol 11, Iss 2, Pp 637-648 (2024)
Abstract Sodium–glucose cotransporter‐2 inhibitors (SGLT2is) reduce morbidity and mortality for heart failure (HF) patients and are recommended as cornerstones for their medical therapy. Utilization in clinical practice remains low for multiple r
Externí odkaz:
https://doaj.org/article/3280496dda1741a2afdb5410ae781340
Autor:
Rongjing Song, Qiaoyu Hou, Xiuying Zhang, Wei Zhao, Gang Liu, Meng Li, Xiaohong Zhang, Linong Ji
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionThe protective effect of sodium–glucose cotransporter-2 (SGLT-2) inhibitors on the kidneys has been widely recognized. However, limited research has reported the changes in estimated glomerular filtration rate (eGFR) of real-world patie
Externí odkaz:
https://doaj.org/article/63345177fe284f7f865284d24240ad6c
Autor:
Kah Suan Chong, Yi-Hsin Chang, Meng-Hsuan Lin, Chien-Ning Hsu, Chi-Chuan Wang, Chih-Yuan Wang, Yun-Lin Huang, Fang-Ju Lin, Huang-Tz Ou
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
IntroductionThere is a lack of real-world evidence regarding the impact of concomitant metformin and renin-angiotensin system inhibitors (RASis) on sodium-glucose cotransporter-2 inhibitor (SGLT2i)-associated kidney outcomes. This study was aimed to
Externí odkaz:
https://doaj.org/article/5cbcafafd07442b7966a6b02ddbde903
Autor:
Qian Wang, Jianmin Yu, Weizhu Deng, Chao Liu, Jian Yang, Yaqing Li, Guangyan Cai, Xiangmei Chen, Zheyi Dong
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundSodium/glucose cotransporter-2 inhibitors (SGLT2i) are associated with cardiovascular benefits. The aim of this systematic review and meta-analysis is to summarize the influence of SGLT2i on the incidence of acute kidney injury (AKI), and t
Externí odkaz:
https://doaj.org/article/9f21d81f0278475f91aefcfec47ae18a